THE Therapeutic Goods
Administration has approved
Actemra (tocilizumab) for the
treatment of systemic juvenile
idiopathic arthritis in patients two
years of age and older.
The approval for juvenile patients
follows the drug’s current availability
for adults with severe active
rheumatoid arthritis on the
Pharmaceutical Benefits Scheme.
Actemra works by blocking the
action of the body’s protein
messenger interleukin-6 which
contributes to chronic inflammation.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 11
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.